Company research
LEXICON PHARMACEUTICALS, INC.
CIK 1062822Updated Sep 26, 2026
SecurityLXRX · NASDAQ · equity
Name history
LEXICON PHARMACEUTICALS, INC./DE · through Dec 5, 2014LEXICON GENETICS INC/TX · through Apr 2, 2007
LXRX price & chart
Loading TradingView…
NASDAQ:LXRX on TradingView ↗About the company
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications.
In the news
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 184,987,000Source | 298,420,000Source | 229,429,000Source | 194,299,000Source |
| Property, Plant and Equipment, NetUSD | 1,863,000Source | 2,484,000Source | 1,987,000Source | 2,071,000Source |
| GoodwillUSD | 44,543,000Source | 44,543,000Source | 44,543,000Source | 44,543,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 34,326,000Source | 66,656,000Source | 22,465,000Source | 46,345,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,384,000Source | 3,473,000Source | 1,010,000Source | 28,000Source |
| Inventory, NetUSD | 281,000Source | 231,000Source | 381,000Source | 0Source |
| Assets, CurrentUSD | 101,895,000Source | 246,193,000Source | 176,547,000Source | 140,866,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,318,000Source | 4,832,000Source | 5,524,000Source | 6,407,000Source |
| Other Assets, NoncurrentUSD | 368,000Source | 368,000Source | 828,000Source | 412,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 77,449,000Source | 152,470,000Source | 136,319,000Source | 77,175,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 366,000Source | 363,000Source | 245,000Source | 189,000Source |
| Additional Paid in CapitalUSD | 2,129,912,000Source | 2,117,325,000Source | 1,862,558,000Source | 1,709,144,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,017,583,000Source | -1,967,242,000Source | -1,766,839,000Source | -1,589,720,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 30,000Source | 119,000Source | 31,000Source | -428,000Source |
| Stockholders' Equity Attributable to ParentUSD | 107,538,000Source | 145,950,000Source | 93,110,000Source | 117,124,000Source |
| Liabilities and EquityUSD | 184,987,000Source | 298,420,000Source | 229,429,000Source | 194,299,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 20,867,000Source | 45,248,000Source | 31,546,000Source | 23,172,000Source |
| Operating Lease, Liability, CurrentUSD | 1,642,000Source | 1,175,000Source | 1,291,000Source | 1,291,000Source |
| Accounts Payable, CurrentUSD | 3,083,000Source | 14,801,000Source | 14,389,000Source | 10,395,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,592,000Source | 4,600,000Source | 5,265,000Source | 5,424,000Source |
| Other Liabilities, NoncurrentUSD | 7,174,000Source | 6,924,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 13,189,000Source | 30,447,000Source | 17,157,000Source | 12,777,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Current MaturitiesUSD | 4,595,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 49,408,000Source | 100,298,000Source | 99,508,000Source | 48,579,000Source |
| Short-term InvestmentsUSD | 61,904,000Source | 171,301,000Source | 147,561,000Source | 92,012,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 621,000Source | 534,000Source | 554,000Source | 427,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,517,000Source | 13,499,000Source | 14,340,000Source | 11,520,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -1,089,000Source | 2,463,000Source | 982,000Source | 14,000Source |
| Increase (Decrease) in InventoriesUSD | 50,000Source | -150,000Source | 381,000Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -67,851,000Source | -178,780,000Source | -161,897,000Source | -88,851,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 113,020,000Source | -15,378,000Source | -49,943,000Source | -71,078,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 1,031,000Source | 470,000Source | 1,326,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 572,000Source | — | — | — |
| Payments for Repurchase of Common StockUSD | — | 1,730,000Source | 824,000Source | 864,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -48,499,000Source | 238,349,000Source | 187,960,000Source | 142,209,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 0Source | -1,307,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,330,000Source | 44,191,000Source | -23,880,000Source | -17,720,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 63,326,000Source | 66,656,000Source | 22,465,000Source | 46,345,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 8,330,000Source | 12,919,000Source | 10,057,000Source | 2,289,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 12,500,000Source | 13,500,000Source | 14,300,000Source | 11,500,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 1,700,000Source | 1,845,000Source | 1,774,000Source | 741,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | 0Source | 0Source | -3,000Source |
| GoodwillUSD | 44,543,000Source | 44,543,000Source | 44,543,000Source | 44,543,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -50,341,000Source | -200,403,000Source | -177,119,000Source | -101,944,000Source |
| Operating Lease, ExpenseUSD | 1,700,000Source | 1,600,000Source | 1,600,000Source | 1,800,000Source |
| Other Nonoperating Income (Expense)USD | 6,909,000Source | 12,293,000Source | 7,732,000Source | 1,596,000Source |
| Payments to Acquire InvestmentsUSD | 139,838,000Source | 328,747,000Source | 223,343,000Source | 133,949,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 0Source | 138,823,000Source | 94,205,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 0Source | — | — |
| Realized Investment Gains (Losses)USD | 0Source | 0Source | 0Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,110,000Source | 0Source |
| Cost of RevenueUSD | 274,000Source | 616,000Source | 85,000Source | 0Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 37,319,000Source | 143,102,000Source | 113,982,000Source | 48,083,000Source |
| Operating Income (Loss)USD | -48,911,000Source | -197,117,000Source | -171,750,000Source | -100,760,000Source |
| Other Nonoperating Income (Expense)USD | 6,909,000Source | 12,293,000Source | 7,732,000Source | 1,596,000Source |
| Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -50,341,000Source | -200,403,000Source | -177,119,000Source | -101,944,000Source |
| Earnings Per Share, BasicUSD per share | -0.14Source | -0.63Source | -0.8Source | -0.62Source |
| Earnings Per Share, DilutedUSD per share | -0.14Source | -0.63Source | -0.8Source | -0.62Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 363,053,000Source | 320,031,000Source | 221,130,000Source | 165,733,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 363,053,000Source | 320,031,000Source | 221,130,000Source | 165,733,000Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 98,714,000Source | 228,198,000Source | 172,954,000Source | 100,899,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Operating Lease, ExpenseUSD | 1,700,000Source | 1,600,000Source | 1,600,000Source | 1,800,000Source |
| Other ExpensesUSD | 8,339,000Source | 15,579,000Source | 13,101,000Source | 2,780,000Source |
| Realized Investment Gains (Losses)USD | 0Source | 0Source | 0Source | 0Source |
| Research and Development ExpenseUSD | 61,121,000Source | 84,480,000Source | 58,887,000Source | 52,816,000Source |
Filing attachments
d32395dex991.htm · 8-K · 2026-02-02
EX-99.1 7 d32395dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES PRICING OF APPROXIMATELY $94.6 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT The Woodlands, Texas, January 29, 2026 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant …
Read attachment ↗d61153dex991.htm · 8-K · 2026-01-29
EX-99.1 2 d61153dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK The Woodlands, Texas, January 29, 2026 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day o…
Read attachment ↗